普鲁卡因胺在慢性非卧床腹膜透析中的应用：一例报告。

Use of procainamide in chronic ambulatory peritoneal dialysis: report of a case.

作者信息

Kroboth P D, Mitchum K, Puschett J B

出版信息

Am J Kidney Dis. 1984 Jul;4(1):78-9. doi: 10.1016/s0272-6386(84)80032-3.

PMID:6204527

Abstract

A patient on chronic ambulatory peritoneal dialysis (CAPD) was treated with procainamide for control of ventricular arrhythmias. A procainamide half-life of 11.5 hours was observed, with a dialysis clearance of 6.5 mL/min. The N-acetylprocainamide (NAPA) dialysis clearance was 5.3 mL/min. The CAPD clearance of procainamide and its active metabolite, NAPA, is much lower than that reported for hemodialysis. Procainamide therapy should be initiated with reduced dosages in patients with renal failure.

摘要

一名接受持续性非卧床腹膜透析（CAPD）的患者因控制室性心律失常而接受普鲁卡因胺治疗。观察到普鲁卡因胺的半衰期为11.5小时，透析清除率为6.5毫升/分钟。N-乙酰普鲁卡因胺（NAPA）的透析清除率为5.3毫升/分钟。普鲁卡因胺及其活性代谢产物NAPA的CAPD清除率远低于血液透析的报道值。肾功能衰竭患者开始普鲁卡因胺治疗时应减少剂量。